Atrophic vulvovaginitis is a condition where the lining of the vagina and vulva becomes thinner, drier, and more fragile due to low levels of estrogen. This condition affects millions of women, particularly after menopause, and can significantly impact quality of life through uncomfortable symptoms. However, many women suffer in silence, unaware that effective treatment options exist to restore comfort and vaginal health.

Understanding Treatment Goals for Atrophic Vulvovaginitis

The main goal of treating atrophic vulvovaginitis is to relieve uncomfortable symptoms and restore the health of vaginal and vulval tissues. This condition causes vaginal dryness, itching, burning, and painful intercourse, along with urinary symptoms like frequent infections and urgency. These symptoms can seriously disrupt daily life and intimate relationships, but they don’t have to be endured as a normal part of aging.^[1]

Treatment success depends on several factors, including the severity of symptoms, whether a woman has other health conditions, and her personal preferences. Some women may find relief with simple over-the-counter measures, while others need prescription treatments. The encouraging news is that medical professionals now recognize this condition as treatable, not just an inevitable consequence of getting older.^[2]

Medical societies worldwide have developed clear guidelines for managing atrophic vulvovaginitis, also known as genitourinary syndrome of menopause (GSM). This newer term acknowledges that the condition affects not just the vagina but also the urinary tract and surrounding tissues. Healthcare providers now understand that addressing these symptoms early can prevent complications like recurrent urinary tract infections and worsening tissue changes over time.^[3]

Beyond the standard treatments that doctors use every day, researchers are also exploring new therapies through clinical trials. These studies investigate innovative approaches that may offer additional options for women who cannot use traditional treatments or who seek alternatives. The landscape of treatment continues to evolve as scientists learn more about how to restore and maintain vaginal health in the absence of adequate estrogen.^[4]

Standard Treatment Approaches

The foundation of treating atrophic vulvovaginitis involves several approaches, starting with the simplest and progressing to more targeted therapies. Healthcare providers typically begin by recommending non-hormonal options before moving to hormonal treatments if needed. This stepped approach allows women to find the least invasive solution that provides adequate relief.^[6]

Non-Hormonal Treatments

Many women find relief by using vaginal moisturizers regularly, typically two to three times per week. These products, which include brands like Replens, K-Y Liquibeads, and Sliquid, work by adding moisture to vaginal tissues and helping them retain water. Unlike lubricants that are used only during sexual activity, moisturizers provide ongoing hydration. The effects of moisturizers generally last longer than lubricants, helping to maintain tissue comfort between applications.^[11]

Water-based lubricants serve a different but complementary purpose. Products like Astroglide, K-Y Jelly, and similar lubricants are applied just before sexual activity to reduce friction and discomfort during intercourse. It’s important to choose lubricants carefully—those containing glycerin or warming ingredients may irritate sensitive tissues in some women. Healthcare providers generally advise avoiding petroleum-based products like petroleum jelly when using latex condoms, as petroleum can break down latex and reduce protection.^[11]

Beyond commercial products, some women successfully use natural oils. Coconut oil, vitamin E oil, and other organic oils can provide lubrication and soothing effects. These options appeal to women who prefer natural remedies or who experience irritation from commercial products. Regular sexual activity itself may help maintain vaginal health by increasing blood flow to the area, which supports tissue vitality even in the absence of adequate estrogen.^[3]

Topical Estrogen Therapy

When non-hormonal approaches don’t provide sufficient relief, doctors typically recommend topical vaginal estrogen. This remains the most effective treatment for atrophic vulvovaginitis. Topical estrogen has a major advantage over pills taken by mouth: it delivers hormone directly to the tissues that need it while minimizing absorption into the bloodstream. This means women can achieve symptom relief with much lower doses of estrogen than would be needed in oral hormone therapy.^[3]

Vaginal estrogen comes in several forms. Creams containing estriol or estradiol can be applied with an applicator or fingertip, usually daily for one to two weeks, then reduced to once or twice weekly for maintenance. Pessaries or tablets, such as Vagifem, are inserted into the vagina using an applicator. Some women prefer a vaginal ring, which is a soft, flexible device placed in the vagina that releases estrogen continuously for three months before needing replacement.^[15]

The benefits of estrogen treatment are well-documented. It normalizes the cells lining the vaginal wall, making them thicker and healthier. Blood flow to the area improves, bringing nutrients and oxygen to tissues. The pH level of the vagina decreases, meaning it becomes more acidic, which is the normal healthy state. This pH change allows beneficial lactobacilli bacteria to return and colonize the vagina. These bacteria help prevent infections by producing lactic acid and competing with harmful organisms. Overall vaginal thickness and elasticity improve, reducing symptoms of dryness, burning, and pain during intercourse.^[3]

Treatment typically begins with a higher-frequency application phase, where estrogen is used daily or several times per week for one to two weeks. This initial phase allows tissues to begin responding and rebuilding. After this, most women transition to a maintenance phase of once or twice weekly use. Some women need to continue treatment indefinitely to maintain symptom relief, as stopping often leads to symptom recurrence. The duration of treatment depends on individual response and ongoing symptoms.^[4]

Systemic Hormone Therapy

Some women taking systemic hormone therapy—estrogen pills, patches, or other forms that deliver hormone throughout the body—still experience vaginal symptoms. Studies suggest that 10% to 20% of women on systemic estrogen may continue to have residual symptoms of atrophic vulvovaginitis. For these women, adding topical vaginal estrogen often provides the additional relief needed. Systemic hormone therapy addresses symptoms like hot flashes and night sweats but may not deliver enough estrogen directly to vaginal tissues.^[7]

Side Effects and Safety Considerations

Topical vaginal estrogen is generally considered safe and well-tolerated. Because only small amounts are absorbed into the bloodstream, the risks associated with systemic hormone therapy are much lower. Women may experience minor side effects such as vaginal discharge, mild irritation, or spotting, especially when first starting treatment. These effects usually diminish as the body adjusts.^[3]

However, certain women need special consideration before starting estrogen therapy. Women with a history of breast cancer or certain other estrogen-sensitive cancers may have concerns about any form of estrogen use. The decision about whether to use topical vaginal estrogen in women with a cancer history remains somewhat controversial and should be made in consultation with both gynecologists and oncologists. Each woman’s situation is unique, and the benefits must be weighed against potential risks.^[7]

General Self-Care Measures

Alongside medical treatments, certain lifestyle measures support vaginal health. Using gentle cleansing practices helps—washing with warm water alone or using a non-soap cleanser once or twice daily avoids irritation. Harsh soaps, douches, perfumed products, deodorants, and powders can all dry and irritate delicate tissues. Women should avoid these products in the genital area.^[3]

Wearing breathable cotton underwear and avoiding tight clothing or synthetic fabrics reduces moisture buildup and irritation. Some medications can contribute to dryness throughout the body, including the vagina—these include antihistamines, decongestants, certain antidepressants, and other drugs with anticholinergic properties. Women taking such medications should discuss potential alternatives with their healthcare provider if dryness becomes problematic.^[3]

Smoking cessation is particularly important. Cigarette smoking decreases estrogen levels in the body and increases the risk and severity of vaginal atrophy. Quitting smoking can help slow the progression of tissue changes and improve overall health. Staying well-hydrated by drinking adequate fluids helps maintain moisture levels throughout the body, including in vaginal tissues.^[4]

Treatment Approaches in Clinical Trials

While standard treatments work well for many women, researchers continue exploring new therapies for atrophic vulvovaginitis. Clinical trials investigate innovative molecules, different delivery methods, and alternative approaches that may benefit women who cannot use or don’t respond to conventional treatments. These studies are essential for expanding treatment options and improving outcomes.^[16]

Selective Estrogen Receptor Modulators

Selective estrogen receptor modulators, or SERMs, represent one area of active research. These compounds interact with estrogen receptors in the body but have tissue-specific effects—they may act like estrogen in some tissues while blocking estrogen effects in others. The theoretical advantage is that a SERM could provide the beneficial effects of estrogen on vaginal tissues while avoiding potential risks in breast tissue or the uterus.^[14]

One SERM that has been studied for vaginal atrophy is ospemifene. This medication is taken as an oral pill rather than applied topically. Clinical trials have examined whether ospemifene can improve vaginal tissue health and reduce symptoms while maintaining a favorable safety profile. Some studies have shown improvements in vaginal cell maturation and symptom relief with this approach. Research continues to evaluate the long-term safety and effectiveness of SERMs for this indication.^[14]

Vaginal Dehydroepiandrosterone (DHEA)

Another approach being studied involves vaginal dehydroepiandrosterone, or DHEA. DHEA is a hormone naturally produced by the adrenal glands that serves as a precursor to both estrogen and testosterone. When applied in the vagina, DHEA is converted locally into estrogen and androgens by enzymes in the tissue. This local conversion theoretically minimizes systemic hormone exposure while providing the active hormones needed for tissue health.^[14]

Clinical trials have investigated vaginal DHEA suppositories, examining their effects on vaginal symptoms and tissue health. Some studies have shown improvements in vaginal dryness, pain during intercourse, and overall vaginal cell health with DHEA treatment. The mechanism involves stimulating the vaginal tissue to produce its own estrogen and testosterone locally, which may offer advantages for women concerned about systemic hormone exposure. Research continues to establish optimal dosing and long-term safety profiles for this treatment approach.^[14]

Non-Hormonal Innovative Therapies

Recognizing that some women cannot or prefer not to use any form of hormone therapy, researchers are exploring completely non-hormonal approaches. One area of investigation involves hyaluronic acid, a substance naturally found in the body that helps tissues retain moisture. Vaginal preparations containing hyaluronic acid are being studied to determine whether they can improve vaginal moisture and tissue health without hormones. Early research suggests possible benefits, though more studies are needed to establish effectiveness compared to standard treatments.^[16]

Another non-hormonal approach under investigation involves certain probiotics. The vagina normally hosts beneficial bacteria, particularly lactobacilli species, which help maintain a healthy acidic environment. When estrogen levels drop, these beneficial bacteria decrease. Researchers are studying whether vaginal or oral probiotics containing specific lactobacilli strains can help restore a healthy vaginal microbiome and improve symptoms. Some studies combining probiotics with low-dose estrogen or phytoestrogens (plant-derived compounds with weak estrogen-like effects) have shown promising results in reducing vaginal dryness and pain during intercourse.^[14]

Vitamin and Supplement Studies

Clinical research has explored whether certain vitamins might benefit vaginal health. Vitamin D has emerged as a compound of interest. Some studies have examined whether vaginal suppositories or creams containing vitamin D can improve tissue health. Research has shown that vitamin D treatment may improve different types of vaginal cells and decrease vaginal pH after several weeks of use. Some studies have combined vitamin D with vitamin E in vaginal formulations, with participants reporting improvements in dryness, itching, and burning after several weeks of treatment.^[20]

While these vitamin-based approaches show promise, more research is needed to understand their true effectiveness compared to standard treatments. Studies examining oral vitamin D supplementation have not shown the same benefits for vaginal tissue as topical application, suggesting that local delivery may be important for this particular benefit.^[20]

Energy-Based Treatments

A newer area of investigation involves energy-based therapies such as laser treatment and radiofrequency therapy. These approaches use controlled energy to heat vaginal tissues, with the goal of stimulating collagen production and tissue remodeling. Proponents suggest these treatments could improve vaginal tissue thickness, elasticity, and moisture without using hormones. Several studies have examined fractional CO2 laser therapy and other energy-based treatments for vaginal atrophy.^[16]

Clinical trials are ongoing to establish the safety and effectiveness of these approaches. Some Phase II studies—which focus on determining whether a treatment works for its intended purpose—have shown improvements in symptoms and tissue characteristics. However, these treatments remain under investigation, and medical societies have called for more rigorous research before recommending them as standard care. Questions remain about optimal treatment parameters, how long benefits last, and whether multiple treatment sessions are needed over time.^[16]

Phase and Location of Clinical Trials

Clinical trials for atrophic vulvovaginitis treatments occur in phases. Phase I trials focus primarily on safety, testing new treatments in small groups to identify any serious side effects. Phase II trials expand to larger groups and examine whether the treatment appears effective while continuing to monitor safety. Phase III trials involve large numbers of participants and compare the new treatment directly to standard treatments or placebo to establish effectiveness and identify more uncommon side effects.^[16]

These studies take place in research centers around the world, including North America, Europe, Australia, and other regions. Women interested in participating in clinical trials should discuss eligibility requirements with their healthcare provider. Participation criteria vary by study but typically include factors like symptom severity, menopausal status, time since menopause, and whether other treatments have been tried. Some trials specifically seek women who cannot use estrogen therapy due to medical conditions, while others compare new treatments to standard estrogen approaches.^[16]

Most common treatment methods

• Vaginal Moisturizers and Lubricants
  • Non-hormonal vaginal moisturizers like Replens, K-Y Liquibeads, and Sliquid applied two to three times per week to restore moisture to vaginal tissues
  • Water-based lubricants such as Astroglide and K-Y Jelly used during sexual activity to reduce discomfort
  • Natural oils including coconut oil and vitamin E preparations for soothing and lubrication
• Topical Vaginal Estrogen
  • Vaginal estrogen creams containing estriol or estradiol applied with an applicator or fingertip, typically daily for 1-2 weeks then once or twice weekly
  • Estrogen pessaries or tablets like Vagifem inserted into the vagina using an applicator
  • Vaginal estrogen rings that release hormone continuously for three months
• Systemic Hormone Therapy
  • Oral estrogen pills, skin patches, or other forms delivering hormone throughout the body for women with multiple menopausal symptoms
  • Often combined with topical vaginal estrogen when vaginal symptoms persist despite systemic therapy
• Selective Estrogen Receptor Modulators (SERMs)
  • Oral medications like ospemifene that provide estrogen-like effects on vaginal tissue while having different effects in other tissues
  • Being studied as alternatives for women who cannot use traditional estrogen therapy
• Vaginal DHEA
  • Suppositories containing dehydroepiandrosterone that is converted locally into estrogen and androgens
  • Minimizes systemic hormone exposure while providing local tissue benefits
• Non-Hormonal Therapies Under Investigation
  • Hyaluronic acid preparations to improve vaginal moisture without hormones
  • Probiotics containing lactobacilli strains to restore healthy vaginal microbiome
  • Vitamin D and vitamin E vaginal treatments to improve tissue health
  • Energy-based therapies including fractional CO2 laser and radiofrequency treatments